Infliximab and adalimumab for uveitis
Purpose: To describe the corticosteroid-sparing success in controlling chronic uveitis in patients treated with TNF alpha inhibitors.
Methods: Retrospective longitudinal case series of patients started on infliximab (n = 31) or adalimumab (n = 12) for chronic noninfectious uveitis at a tertiary referral center. The main outcome was corticosteroid-sparing success. Secondary outcomes were sustained control of inflammation regardless of corticosteroid-sparing effect, tapering of concurrent nonbiologic therapy, and discontinuation.
Results: Sustained control of inflammation with corticosteroid-sparing success on infliximab and adalimumab, respectively, was achieved in 33.3 and 37.5% at 3 months, 60.7 and 62.5% at 6 months, and 60.9 and 57.1% at 12 months. Median time to this outcome was 98 days for infliximab and 169 days for adalimumab. Six infliximab patients had adverse reactions.
Conclusions: Infliximab and adalimumab improve control of ocular inflammation and are successful corticosteroid-sparing agents. However, time to corticosteroid-sparing control of inflammation may take a few months with either agent, and adverse reactions may limit treatment
Martel, J. N., Esterberg, E., Nagpal, A., & Acharya, N. R. (2012). Infliximab and adalimumab for uveitis. Ocular Immunology and Inflammation, 20(1), 18-26. DOI: 10.3109/09273948.2011.633205